Detection of naltrexone and naltrexol in patients prescribed Embeda®

Authors

  • Robert West, MS
  • Maria Guevara, PharmD
  • Charles Mikel, PhD

DOI:

https://doi.org/10.5055/jom.2017.0380

Keywords:

detection, naltrexone, naltrexol, Embeda

Abstract

no abstract

Author Biographies

Robert West, MS

Director of Toxicology and Regulatory Affairs, Millennium Health, LLC, San Diego, California

Maria Guevara, PharmD

Millennium Health, LLC, San Diego, California

Charles Mikel, PhD

Millennium Health, LLC, San Diego, California

References

Embeda [package insert]. New York, NY: Pfizer Pharmaceuticals, Inc; 2016.

Downloads

Published

05/01/2017

How to Cite

West, MS, R., M. Guevara, PharmD, and C. Mikel, PhD. “Detection of Naltrexone and Naltrexol in Patients Prescribed Embeda®”. Journal of Opioid Management, vol. 13, no. 3, May 2017, pp. 139-40, doi:10.5055/jom.2017.0380.

Issue

Vol. 13 No. 3 (2017): May/June

Section

Letters to the Editor

License

Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved

Crossref
Scopus
Google Scholar
Europe PMC